2025 Q3 -tulosraportti
100 päivää sitten
‧1 t 0 min
Tarjoustasot
Määrä
Osto
1 279
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
17,63VWAP
Alin
16,81VaihtoMäärä
115,1 12 257 912
VWAP
Ylin
17,63Alin
16,81VaihtoMäärä
115,1 12 257 912
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 23.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 3.11.2025 | ||
2025 Q2 -tulosraportti 4.8.2025 | ||
Vuosittainen yhtiökokous 2025 12.6.2025 | ||
2025 Q1 -tulosraportti 5.5.2025 | ||
2024 Q4 -tulosraportti 24.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·21 t sittenI really hope they get such a beating in the upcoming lawsuit with Novo that they realize they shouldn't freeload on others, really good if they are sentenced to pay back so much that they go bankrupt, yes, you guessed right, I myself have shares in Novo Nordisk
·18 t sittenI cannot see any reason why a billion-dollar company should go bankrupt, but considering the stock beatings they are getting, they should probably stick to what they are best at, and stop breaking agreements and patents.·1 t sittenIt will cost H&H a couple of hundred million dollars, and probably a significant amount on goodwill. For Novo, the case will set a precedent, and deter others from similar stunts.
·23 t sitten · MuokattuI own shares in HIMS, and it's no secret here that I am extremely bullish on the company. Therefore, in light of Novo's lawsuit, I have made a video about why I have bought more HIMS. https://www.youtube.com/watch?v=FUikNVIdoW8
·23 t sittenBut the management is good, because they copy a patented product and sell it for 1/3 of the price?.... In my world, it fits reasonably well that Hims must be considered lazy or incompetent, as they either don't care about the law or have no knowledge of what a patent is? If you look at key figures for Hims, it certainly doesn't show that the company is being traded as if they are about to go bankrupt. They are traded based on the uncertainty of what economic consequences it might have for Hims when they are sued. Being sued is, of course, not something an investor or company is interested in. Regarding whether the management is incompetent, it must be said that there is a fair assessment here that they are. Why else make a big announcement that you are offering the Wegovy pill for 49 dollars per month, and 2 days later remove the product. So, laziness and/or lack of knowledge must be said to be present in the management, no matter how you look at it. Personally, I have written previously that I would not be surprised if the company does not exist within the next 5 years, precisely because of the management's actions and the way their business is run - if they want to survive, they must sell patent-protected medicine via agreements with e.g. Novo, Lilly and others. Or they must sell medicine that has gone off patent. This is, of course, just my own opinion and view :)
·13 t sittenWell-written Belfort. It will be exciting and yes, it is cases like these that can destroy the company. Following with excitement and somewhat hoping Kåre S. once again gets a smackdown from Novo Nordisk. He only gets more and more bitter with time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
100 päivää sitten
‧1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·21 t sittenI really hope they get such a beating in the upcoming lawsuit with Novo that they realize they shouldn't freeload on others, really good if they are sentenced to pay back so much that they go bankrupt, yes, you guessed right, I myself have shares in Novo Nordisk·18 t sittenI cannot see any reason why a billion-dollar company should go bankrupt, but considering the stock beatings they are getting, they should probably stick to what they are best at, and stop breaking agreements and patents.·1 t sittenIt will cost H&H a couple of hundred million dollars, and probably a significant amount on goodwill. For Novo, the case will set a precedent, and deter others from similar stunts.
- ·23 t sitten · MuokattuI own shares in HIMS, and it's no secret here that I am extremely bullish on the company. Therefore, in light of Novo's lawsuit, I have made a video about why I have bought more HIMS. https://www.youtube.com/watch?v=FUikNVIdoW8·23 t sittenBut the management is good, because they copy a patented product and sell it for 1/3 of the price?.... In my world, it fits reasonably well that Hims must be considered lazy or incompetent, as they either don't care about the law or have no knowledge of what a patent is? If you look at key figures for Hims, it certainly doesn't show that the company is being traded as if they are about to go bankrupt. They are traded based on the uncertainty of what economic consequences it might have for Hims when they are sued. Being sued is, of course, not something an investor or company is interested in. Regarding whether the management is incompetent, it must be said that there is a fair assessment here that they are. Why else make a big announcement that you are offering the Wegovy pill for 49 dollars per month, and 2 days later remove the product. So, laziness and/or lack of knowledge must be said to be present in the management, no matter how you look at it. Personally, I have written previously that I would not be surprised if the company does not exist within the next 5 years, precisely because of the management's actions and the way their business is run - if they want to survive, they must sell patent-protected medicine via agreements with e.g. Novo, Lilly and others. Or they must sell medicine that has gone off patent. This is, of course, just my own opinion and view :)·13 t sittenWell-written Belfort. It will be exciting and yes, it is cases like these that can destroy the company. Following with excitement and somewhat hoping Kåre S. once again gets a smackdown from Novo Nordisk. He only gets more and more bitter with time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1 279
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
17,63VWAP
Alin
16,81VaihtoMäärä
115,1 12 257 912
VWAP
Ylin
17,63Alin
16,81VaihtoMäärä
115,1 12 257 912
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 23.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 3.11.2025 | ||
2025 Q2 -tulosraportti 4.8.2025 | ||
Vuosittainen yhtiökokous 2025 12.6.2025 | ||
2025 Q1 -tulosraportti 5.5.2025 | ||
2024 Q4 -tulosraportti 24.2.2025 |
2025 Q3 -tulosraportti
100 päivää sitten
‧1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 23.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 3.11.2025 | ||
2025 Q2 -tulosraportti 4.8.2025 | ||
Vuosittainen yhtiökokous 2025 12.6.2025 | ||
2025 Q1 -tulosraportti 5.5.2025 | ||
2024 Q4 -tulosraportti 24.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·21 t sittenI really hope they get such a beating in the upcoming lawsuit with Novo that they realize they shouldn't freeload on others, really good if they are sentenced to pay back so much that they go bankrupt, yes, you guessed right, I myself have shares in Novo Nordisk·18 t sittenI cannot see any reason why a billion-dollar company should go bankrupt, but considering the stock beatings they are getting, they should probably stick to what they are best at, and stop breaking agreements and patents.·1 t sittenIt will cost H&H a couple of hundred million dollars, and probably a significant amount on goodwill. For Novo, the case will set a precedent, and deter others from similar stunts.
- ·23 t sitten · MuokattuI own shares in HIMS, and it's no secret here that I am extremely bullish on the company. Therefore, in light of Novo's lawsuit, I have made a video about why I have bought more HIMS. https://www.youtube.com/watch?v=FUikNVIdoW8·23 t sittenBut the management is good, because they copy a patented product and sell it for 1/3 of the price?.... In my world, it fits reasonably well that Hims must be considered lazy or incompetent, as they either don't care about the law or have no knowledge of what a patent is? If you look at key figures for Hims, it certainly doesn't show that the company is being traded as if they are about to go bankrupt. They are traded based on the uncertainty of what economic consequences it might have for Hims when they are sued. Being sued is, of course, not something an investor or company is interested in. Regarding whether the management is incompetent, it must be said that there is a fair assessment here that they are. Why else make a big announcement that you are offering the Wegovy pill for 49 dollars per month, and 2 days later remove the product. So, laziness and/or lack of knowledge must be said to be present in the management, no matter how you look at it. Personally, I have written previously that I would not be surprised if the company does not exist within the next 5 years, precisely because of the management's actions and the way their business is run - if they want to survive, they must sell patent-protected medicine via agreements with e.g. Novo, Lilly and others. Or they must sell medicine that has gone off patent. This is, of course, just my own opinion and view :)·13 t sittenWell-written Belfort. It will be exciting and yes, it is cases like these that can destroy the company. Following with excitement and somewhat hoping Kåre S. once again gets a smackdown from Novo Nordisk. He only gets more and more bitter with time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1 279
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
17,63VWAP
Alin
16,81VaihtoMäärä
115,1 12 257 912
VWAP
Ylin
17,63Alin
16,81VaihtoMäärä
115,1 12 257 912
Välittäjätilasto
Dataa ei löytynyt